FDA re­ports short­age of No­vo Nordisk's weight loss drug Sax­en­da

No­vo Nordisk is fac­ing an­oth­er short­age of one of its block­buster drugs; this time it’s the weight loss drug li­raglu­tide, bet­ter known as Sax­en­da.

Ac­cord­ing to the FDA’s drug short­age data­base, there will be lim­it­ed avail­abil­i­ty of the 6 mg/ml ver­sion of Sax­en­da and the Sax­en­da pen through the end of the year. A No­vo Nordisk spokesper­son said that ris­ing de­mand for weight man­age­ment med­i­cines has “put pres­sure on the sup­ply” of No­vo’s weight loss prod­ucts, in­clud­ing Sax­en­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER